CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

CommonSpirit Health

Paul Rains, System SVP Behavioral Health

The Rollercoaster of Behavioral Health Care

Paul Rains

Paul Rains

Rollercoasters are supposed to be fun, but not when they apply to the delivery of behavioral health. In our American healthcare system, we have made some major strides with several diseases, yet not with behavioral health. Unfortunately, our behavioral health patients still face many of the same issues that they’ve faced in the past. However, there is hope on the horizon.


Going down…


Mental health disorders are chronic diseases, just like diabetes. The challenge lies in that expected outcomes are often less clearly defined than those we have in other medical diseases. Continuing the metaphor of diabetes, we can follow response to treatment based on objective measures like glucose and kidney function, then make rational treatment decisions based on those numbers. A similar metric is much less clear in, for example, schizophrenia. Because of this, attempts to define “standard treatment” for mental health disorders have been elusive.


The challenge, then, for payers is that outcomes and expenditures are often difficult to predict. Payers can predict costs for the treatment of a tumour, for example, but not as much for major depression. For general health care, third-party payers can allocate funds based on tables of known outcomes. However, the outcomes are often not known in mental health. Government and private payers are often seriously underfunded, and the funding for mental health care in our country has not even kept pace with inflation. They are being asked to do more with less.


There are serious barriers to receiving care in behavioral health. There are personal and cultural barriers, with stigma being a major obstacle in several populations. Attempts to destigmatize mental health care have met with some powerful successes as well as many failures. Not all insurance programs cover mental health care, and out-of-pocket costs can become prohibitive. Effective care may require multiple weekly visits, making compliance an issue for people with jobs or limited transportation. Laws passed in the past few decades to protect patient privacy have created a new layer of difficulty when it comes to information sharing, and building a comprehensive multidisciplinary system of care is more challenging when each provider is only allowed access to limited information regarding a patient.


Given these barriers, each party—patients, providers, health care systems, third-party payers, and government programs—have each created well-meaning approaches to care resulting in a system that is disjointed, inefficient, and poorly accessible, sometimes with different components acting at odds with each other. Each party is pointing fingers at each other.


Going up…


There is hope for this quagmire. As in most human conditions, the answers lie first in communication. New technologies have enabled effective communication using encryption methods that guarantee patient privacy. Using secure communications, including e-mail and video conferencing, stakeholders can work together in real-time to develop optimum individualized and evidence-based care systems. Video conferencing has also led to the increased use of telehealth, video therapy sessions, video group sessions, and video care team meetings. Today, that team of experts can extend beyond a single zip code to include thought leaders worldwide.


Artificial intelligence (AI) has the potential to dramatically impact behavioural health care. AI can help with effective communication, especially in patient-facing applications where explanations developed by AI are generally more comprehensive and well-written than those created by humans. AI is based on big data and works best with data. As we understand the power of combining genetics, epigenetics, nutrition, biomarkers, functional MRIs, PET scans, population demographics, environmental toxins, weather, and a host of other data points as they may apply to a single patient, we will see dramatic improvements in care outcomes, access, treatments, and costs.


Buckle up…


Behavioral healthcare has indeed been an exciting rollercoaster ride. Hop in, fasten your seatbelt and restraints, and get ready for the ride of your life. This will be epic!


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.
The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/cxoinsight/the-rollercoaster-of-behavioral-health-care-nwid-3016.html